Clinical Decision Support in Gastroenterology: Why General Medical AI Keeps Falling Short

Clinical scenario

A 61-year-old male with compensated cirrhosis (Child-Pugh B, MELD-Na 14) presents with a two-day history of low-grade confusion, increased abdominal girth, and a serum sodium of 129. His last paracentesis was three weeks ago. Outpatient lactulose compliance is uncertain. He is not febrile, and his creatinine has risen from 0.9 to 1.4 over four weeks.

The attending types this presentation into Glass Health. The differential returns hepatic encephalopathy, hyponatremic encephalopathy, and spontaneous bacterial peritonitis - all correct, all appropriate. What the response does not do: it does not apply the West Haven Criteria to grade the encephalopathy, it does not flag that a creatinine rise from 0.9 to 1.4 in a cirrhotic patient meets criteria for acute kidney injury requiring diagnostic paracentesis to exclude SBP regardless of fever, and it does not reason through whether this patient's sodium trajectory puts him at risk for osmotic demyelination if correction is too aggressive. These are not obscure nuances - they are the decisions that determine whether this patient is managed safely as an outpatient, admitted to a general ward, or escalated to hepatology. A tool that generates a correct but operationally inert differential has not provided clinical decision support. It has provided reassurance.

Why GI complexity defeats horizontal AI platforms

The subspecialty problem in AI for gastroenterologists and hepatology is structural, not incidental. General platforms are trained to perform well across medicine broadly - which means their reasoning is calibrated for the median clinical scenario, not the complex GI case. Three specific failure modes recur.

First, scoring systems. Gastroenterology and hepatology run on validated scoring tools - MELD-Na for transplant listing, Harvey-Bradshaw for Crohn's activity, the Baveno VII criteria for varices screening, Glasgow-Blatchford for upper GI bleeding triage, Lille score for alcoholic hepatitis steroid response. These are not optional enhancements to clinical reasoning; they are the reasoning. A platform that cannot apply them accurately and interpret them contextually is generating informed-sounding prose, not clinical decision support. Glass Health, reviewed extensively in 2026, explicitly does not provide drug dosing or evidence citations - both of which are inseparable from scoring-based GI management.

Second, guideline specificity. The ACG, ASGE, EASL, and ECCO publish subspecialty guidelines that are detailed, frequently updated, and clinically decisive. When a GI fellow asks whether to test for H. pylori after a negative biopsy in a patient on PPIs, the answer depends on whether the test used was a urea breath test, stool antigen, or rapid urease test - and the 2023 ACG H. pylori guidelines address this directly. A generalist AI trained on broad medical corpora will approximate this answer. A tool built around current subspecialty guidance will give it precisely. For AI GI fellows and residents in training, the difference between an approximate answer and a precise one is not academic - it shapes clinical habits that persist for decades.

Third, evidence currency. The IBD biologic landscape changed materially between 2022 and 2025. JAK inhibitor positioning, the ECCO guidance on IL-12/23 inhibitors, updated STRIDE-II treat-to-target criteria - these are clinically active decisions in every moderate-to-severe IBD follow-up. A platform not specifically updated against subspecialty GI literature will lag in exactly the areas that matter most.

A frequently overlooked point about AI adoption in GI

The most expensive failure mode in clinical AI is not the tool that gives a wrong answer - it is the tool that gives a confidently incomplete one. A gastroenterologist who receives a polished, well-structured response that stops just short of the decision they need will either fill the gap with their own judgment (no harm done, no benefit gained) or, more dangerously in a trainee, mistake comprehensiveness of format for completeness of reasoning. General tools are very good at looking thorough. Subspecialty clinical decisions in GI require more than a well-organized differential. They require a tool that knows what question comes next.

Bottom line for clinical practice

• Ambient scribing tools (Nabla, Corti) solve the documentation burden well - adopt them for that purpose, but do not expect them to reason through a hepatic encephalopathy grading or a Baveno VII varices decision.

• Glass Health's differential diagnosis engine is useful for case structuring and trainee education, but independent reviewers confirm it provides no evidence citations and limited reliability on complex multi-system presentations - both of which are routine in GI hepatology.

• Scoring systems are not optional add-ons in GI - MELD-Na, Glasgow-Blatchford, Lille, Harvey-Bradshaw, and others are clinical decisions. Any AI tool for gastroenterologists that cannot apply and contextualise these is providing partial support at best.

• Current ASGE and ACG guidance on AI in GI clinical practice specifically calls for tools that generate real-world evidence on patient outcomes - not just documentation efficiency. Hold AI tools to that standard before integrating them into complex case management.

• For GI fellows building clinical reasoning habits: the tool you train with shapes how you think. A tool that approximates subspecialty answers is a worse teacher than one that reasons from current GI guidelines explicitly.

When you're in clinic and the case is moving faster than a textbook chapter can keep up with - a decompensating cirrhotic, a steroid-refractory IBD flare, an upper GI bleed where the Glasgow-Blatchford score changes your triage decision - the gap between a general AI response and a GI-specific one is not a matter of preference. Walk the case through GastroAGI → and see what subspecialty clinical decision support in gastroenterology actually looks like.